Stocklytics Platform
Asset logo for symbol PCVX
Vaxcyte
PCVX41
$111.58arrow_drop_down0.46%-$0.52
Asset logo for symbol PCVX
PCVX41

$111.58

arrow_drop_down0.46%

AI Deep-Learning Forecast (PCVX)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Vaxcyte (PCVX) Stocklytics Forecast

The stock price of Vaxcyte, Inc. (PCVX) has been the subject of much speculation and prediction in recent times. Investors are keen to know what the future holds for this biotechnology company. While it is difficult to predict the exact stock price for PCVX, market analysts and experts have offered their forecasts and price targets.
According to analysts, the stock price of Vaxcyte, Inc. (PCVX) is expected to witness positive growth in the coming years. With its focus on developing innovative vaccines, Vaxcyte has garnered significant attention and investor interest. The company's current and future pipeline of vaccine candidates, particularly in the areas of pneumococcal disease and Lyme disease, is viewed as highly promising. This has led many analysts to project an increase in the company's stock price.
add Vaxcyte to watchlist

Keep an eye on Vaxcyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Vaxcyte (PCVX) stock?

Analysts have set a target price of $63 for Vaxcyte (PCVX), based on forecasts from 13 analysts. The predicted price range extends from a high of $80 to a low of $40. This represents a potential increase of up to -28.3% and a decrease of -64.15% from the current price of $111.58. These forecasts are as of 2020 Jul 07.
help

What are the analyst ratings for Vaxcyte (PCVX) stock?

Currently, there are no analyst ratings available for Vaxcyte (PCVX), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Vaxcyte (PCVX) stock?

At present, there is no AI or machine-learning-based price prediction available for Vaxcyte (PCVX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media